The Precision Peptide Company Inc.
PNGAF
$0.32
-$0.02-6.10%
OTC PK
| 04/30/2026 | 01/31/2026 | 10/31/2025 | 07/31/2025 | 04/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 9,850.00% | 2,080.65% | 298.89% | -49.50% | -96.64% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 9,850.00% | 2,080.65% | 298.89% | -49.50% | -96.64% |
| Cost of Revenue | 3,327.27% | -44.69% | -61.54% | -97.01% | -98.86% |
| Gross Profit | 14,033.33% | 197.67% | 136.74% | 103.53% | 99.59% |
| SG&A Expenses | 273.41% | 268.63% | 125.92% | 68.69% | -10.93% |
| Depreciation & Amortization | 65,900.00% | 21,900.00% | 13,100.00% | 3,511.11% | -87.50% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 284.78% | 254.68% | 118.53% | 56.73% | -18.42% |
| Operating Income | -274.20% | -246.96% | -116.37% | -58.20% | 16.26% |
| Income Before Tax | -467.27% | -464.04% | -334.56% | -61.82% | 12.23% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -467.27% | -464.04% | -334.56% | -61.82% | 12.23% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -467.27% | -464.04% | -334.56% | -61.82% | 12.23% |
| EBIT | -274.20% | -246.96% | -116.37% | -58.20% | 16.26% |
| EBITDA | -265.20% | -240.21% | -111.30% | -56.71% | 16.40% |
| EPS Basic | -28.54% | -7.66% | 5.44% | 19.08% | 39.30% |
| Normalized Basic EPS | 13.66% | 27.05% | 38.24% | 19.34% | 39.74% |
| EPS Diluted | -28.54% | -7.66% | 5.44% | 19.08% | 39.30% |
| Normalized Diluted EPS | 13.66% | 27.05% | 38.24% | 19.34% | 39.74% |
| Average Basic Shares Outstanding | 280.89% | 362.98% | 265.41% | 140.58% | 59.93% |
| Average Diluted Shares Outstanding | 280.89% | 362.98% | 265.41% | 140.58% | 59.93% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |